Publications by authors named "Maria Palmisano"

Claim this Profile
R
Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy.
Samira Merali, David H Salinger, Maria Palmisano, Amy J Sehnert, Neelima Thanneer

CPT Pharmacometrics Syst Pharmacol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration.
Peter Chang, Vidya Perera, David H Salinger, Samira Merali, Neelima Thanneer, Maria Palmisano

CPT Pharmacometrics Syst Pharmacol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Omeprazole and Verapamil on the Pharmacokinetics, Safety, and Tolerability of Mavacamten: Two Drug-Drug Interaction Studies in Healthy Participants.
Vidya Perera, Daniel D Gretler, Julie D Seroogy, Manting Chiang, Maria Palmisano

Clin Pharmacol Drug Dev· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype.
Manting Chiang, Caroline Sychterz, Vidya Perera, Samira Merali, Maria Palmisano

Clin Pharmacol Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, and Antifibrotic Activity of CC-90001 (BMS-986360), a c-Jun N-Terminal Kinase Inhibitor, in Pulmonary Fibrosis.
Gerald Horan, Ying Ye, Mary Adams, Anastasia Parton, Dorota Cedzik, Maria Palmisano

Clin Pharmacol Drug Dev· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, and Pharmacodynamics of CC-90001 (BMS-986360), a c-Jun N-terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants.
Ying Ye, Allison Gaudy, Michael Thomas, Josephine Reyes, Barbara Burkhardt, Maria Palmisano

Clin Pharmacol Drug Dev· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.
Yizhe Chen, Ken Ogasawara, Rebecca Wood-Horrall, Mark Thomas, Michael Thomas, Maria Palmisano

Cancer Chemother Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production.
Rajula Gaur, Kofi A Mensah, Jason Stricker, Mary Adams, Anastasia Parton, Maria Palmisano

Arthritis Res Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety.
Wei Gao, Hongxiang Hu, Lipeng Dai, Miao He, Hebao Yuan, Maria Palmisano

Acta Pharm Sin B· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
Ken Ogasawara, Rebecca N Wood-Horrall, Mark Thomas, Michael Thomas, Liangang Liu, Maria Palmisano

Cancer Chemother Pharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure-response analysis of pomalidomide.
Ken Ogasawara, Nastya Kassir, Xiaomin Wang, Bouchra Benettaib, Simon Zhou, Maria Palmisano

Pediatr Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
Ken Ogasawara, Jeanelle Kam, Mark Thomas, Liangang Liu, Mary Liu, Maria Palmisano

Cancer Chemother Pharmacol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Xin Luan, Hebao Yuan, Yudong Song, Hongxiang Hu, Bo Wen, Maria Palmisano

Biomaterials· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and tolerability of apremilast in healthy Korean adult men.
Ki Young Huh, Yewon Choi, Jim Nissel, Maria Palmisano, Xiaomin Wang

Clin Transl Sci· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator.
Ying Ye, Allison Gaudy, Peter Schafer, Michael Thomas, Daniel Weiss, Maria Palmisano

Clin Pharmacol Drug Dev· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
Sekhar Surapaneni, Usha Yerramilli, April Bai, Deepak Dalvie, Jennifer Brooks, Maria Palmisano

Drug Metab Dispos· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.
Ken Ogasawara, Christine Xu, Jian Yin, Borje Darpo, Leon Carayannopoulos, Maria Palmisano

Clin Pharmacol Drug Dev· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
Allison Gaudy, Christian Atsriku, Ying Ye, Kimberly MacGorman, Liangang Liu, Maria Palmisano

Eur J Clin Pharmacol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects.
Emily Briggs, Sunny Chapel, Peijin Zhang, Maria Palmisano, Jonathan Q Tran

CPT Pharmacometrics Syst Pharmacol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.
Nianhang Chen, Nastya Kassir, Abderrahmane Laadem, Ana Carolina Giuseppi, Jeevan Shetty, Maria Palmisano

J Clin Pharmacol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects.
Jonathan Q Tran, Peijin Zhang, Susan Walker, Atalanta Ghosh, Mary Syto, Maria Palmisano

Adv Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
Jonathan Q Tran, Peijin Zhang, Atalanta Ghosh, Liangang Liu, Mary Syto, Maria Palmisano

Adv Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Excretion balance and pharmacokinetics following a single oral dose of [C]-fedratinib in healthy subjects.
Ken Ogasawara, Christine Xu, Vanaja Kanamaluru, Nicholas Siebers, Sekhar Surapaneni, Maria Palmisano

Cancer Chemother Pharmacol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies.
Yan Li, Maria Palmisano, Duxin Sun, Simon Zhou

Clin Pharmacol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach.
Xiaomin Wang, Jian Chen, Josephine Reyes, Simon Zhou, Maria Palmisano

Oncol Ther· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis